A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.

by Craig R Cohen, Joelle Brown, Anna-Barbara Moscicki, Elizabeth A Bukusi, Jeremy R A Paull, Clare F Price, Stephen Shiboski
Published 2011-01-01

A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.

by Arthur S Waldbaum, Jane R Schwebke, Jeremy R A Paull, Clare F Price, Stephanie R Edmondson, Alex Castellarnau, Philip McCloud, George R Kinghorn
Published 2020-01-01

A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis

by Jane R. Schwebke, Belvia A. Carter, Arthur S. Waldbaum, Kathy J. Agnew, Jeremy R.A. Paull, Clare F. Price, Alex Castellarnau, Philip McCloud, George R. Kinghorn
Published 2021-04-01

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

by Clare F Price, David Tyssen, Secondo Sonza, Ashley Davie, Sonya Evans, Gareth R Lewis, Shirley Xia, Tim Spelman, Peter Hodsman, Thomas R Moench, Andrew Humberstone, Jeremy R A Paull, Gilda Tachedjian
Published 2011-01-01